Step 1
Draft
Step 2
Unite with Fellow Investors
Step 3
Choose the Best Attorney
Step 4
Provide Documents
Step 5
Follow Case Progress
Step 6
Get Payout
FGEN.US
id: 892
FibroGen (FGEN) $28.5M Shareholder Settlement
The settlement funds have been distributed to claimants.
$28,500,000
Cash SettlementN.D. California
Court3:21-cv-2623
Case number12/20/2018
Class period Start07/15/2021
Class period End06/12/2024
Claim deadlineFibroGen (FGEN) agreed to settle $28 million with investors to end claims over hiding information about its anemia treatment candidate Roxadustat.
Case Details:
FibroGen and its leaders were accused of not revealing important details about the Roxadustat Phase 3 program.
They supposedly provided false information about the drug's safety.
Moreover, FibroGen's analyses suggested higher risks and doubts about Roxadustat's FDA approval emerged.
On this news, $FGEN dropped when the truth came out.
FibroGen has now decided to resolve all the allegations and pay a $28.5M settlement.
Case Type
US Securities Class Action
Case Status
Disbursed
Alleged Offence
Mismanagement,
Misleading Statements,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Filing date
04/12/2021
Plaintiffs
Peifa Xu
Attorneys
Bernstein Litowitz Berger & Grossmann LLP, Saxena White PA (Boca Raton, FL)
Defendants
Enrique Conterno, James Schoeneck, K. Peony Yu
Judge
Edward M Chen
Class wide damages
$603,100,000
Trades matching type
FIFO
Disbursement date
01/15/2025
Frequently Asked Questions
Who is eligible for this settlement?
Do I have to sell securities to be eligible?
How long does the payout process take?
What is 11thestate?
Trusted by industry leaders
Endorsed by top professionals who trust our innovative solutions to drive impactful results.